Table 3 Relationship between quality of life and inhibitor development, treatment type, haemophilia severity and the consumption of drugs for pain control

Physical functioning

0.15ª

17.22 *

-32.56 - -1.88

3.29

-6.68

-17.30–3.93

0.54

25.28 **

12.64–37.91

0.11

21.50 **

12.03–30.96

Role-physical

1.18ª

18.12 *

-35.41 - -0.84

2.66ª

-13.06

-24.39 - -1.73

3.15

20.40 **

6.01–34.78

13.63ª

27.80 **

20.32–35.37

Body pain

0.00

8.62

-21.44–4.19

0.13

-8.38

-18.61–1.83

0.003

17.78 **

4.98–30.58

0.26

27.36 **

19.06–35.65

General health

2.75

2.33

-13.18–8.51

1.27

-4.28

-12.94–4.36

2.32

16.81 **

6.21–27.40

0.72

15.85 **

7.99–23.71

Vitality

0.70

2.59

-8.55–3.35

5.01

0.49

-4.30–5.28

1.39

7.62 *

1.68–13.57

4.17ª

10.00 **

6.63–13.38

Social functioning

0.47

8.63

-23.63–6.37

0.13

-1.22

-5.66–6.64

0.35

16.79 *

1.61–31.98

0.76

20.88 **

9.82–31.93

Role-emotional

0.35

-0.71

-7.71–9.14

0.17

-1.15

-13.34–10.90

6.17ª

5.83 **

2.30–9.36

14.56ª

7.13 **

2.86–11.40

Mental health

0.09

1.08

-7.34–5.17

0.86

-0.82

-7.90–5.59

6.80ª

7.50 **

3.84–11.16

16.08ª

9.45 **

6.16–12.74

Physical component score

0.31ª

6.20 *

-12.70–0.28

0.51

-3.83

-5.84–4.19

0.11

9.72 **

4.78–14.66

4.39ª

10.60 **

7.63–13.58

Mental component score

0.21

-1.40

-2.03–4.84

1.05

1.23

-7.92–0.25

2.40

1.20

-2.36–4.76

1.44

2.27

-0.41–4.96